BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharmaceutical company headquartered in Stockholm, Sweden, dedicated to developing disease-modifying treatments and diagnostics for severe brain diseases. The company's core mission is to make a significant difference for patients suffering from neurodegenerative disorders, striving for a future where science can overcome these debilitating conditions.

BioArctic's portfolio primarily focuses on innovative biological drugs, particularly antibodies, targeting neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). A key product is lecanemab (BAN2401), an FDA-approved immunotherapy for Alzheimer's disease, developed in collaboration with its partner Eisai. The company also leverages its proprietary BrainTransporter™ technology, designed to enhance the delivery of drugs across the blood-brain barrier, thereby improving treatment efficacy.

Under the leadership of CEO Gunilla Osswald, BioArctic maintains a strong market position through strategic collaborations with global pharmaceutical companies. Recent notable developments include the continued global approvals and royalty generation from lecanemab, as well as new partnerships. In 2025, BioArctic signed an option, collaboration, and license agreement with Novartis Pharma AG, involving an upfront payment of $30 million, to utilize its BrainTransporter™ technology for a new neurodegeneration treatment. The company also reported record-high profits in its 2025 Annual Report.